With the rise of metabolic disorders, commonly subsumed under the term “metabolic syndrome”, over the last decades, PPAR proteins have emerged as interesting therapeutic targets to counter pathological conditions such as obesity, Type 2 diabetes (T2D), insulin resistance, Nonalcoholic fatty liver disease (NAFLD), Nonalcoholic steatosis (NASH), dyslipidema, and hypertension [1,2]. This evidence concerns the gene PPARA and Other metabolic disease.